Prescribing physicians play a large role in the adoption of biosimilars for the treatment of patients with rheumatic diseases, so it is important to understand physicians’ perceptions of which patients are suitable for treatment with biosimilars in clinical practice.
A study of physicians in the European Union suggests that physicians were more likely to consider rheumatoid arthritis (RA) patients suitable for biosimilar infliximab when,
The investigators performed a medical chart review of RA patients of physicians (primarily rheumatologists) in hospitals and private practices in the United Kingdom, France, Germany, Italy, and Spain to collect de-identified data on patient diagnoses, treatment patterns, dynamics, and patient symptomology and disease status. Physicians identified whether patients were suitable for biosimilar infliximab, and if they were, rated how likely they would be to prescribe the product to them when it became available. [Biosimilar infliximab (Inflectra/Remsima) was approved by the EMA in September 2013.] The analysis compared patients who were considered suitable for biosimilar infliximab with those who were not considered suitable per physician judgment, excluding those who previously failed infliximab.
Patients currently on (or discontinued within the past 3 months) a biologic drug and who were visiting each center during the screening period were selected for medical chart review. A total of 1204 patients were included in the analysis, 425 of whom were identified by the physicians as being suitable for biosimilar infliximab. Fifty-five percent of these were rated greater than or equal to 5 and 26% at 4, on their likelihood of being prescribed the infliximab biosimilar (7, extremely likely; 1, not at all likely). The physicians were screened for practice duration and patient volume, and were recruited to be geographically representative.
The study also concluded that physicians were not “readily prepared to prescribe the biosimilar to all infliximab biosimilar—suitable RA patients,” and the authors recommend studying this issue further to understand the drivers behind physician perception of which RA patients are suitable for treatment with biosimilar infliximab.
Among physicians, concerns about switching patients from Remicade to biosimilar infliximab remain because the approved infliximab biosimilar has not been designated as interchangeable by the FDA. Some studies have suggested that biosimilar switching is not suitable for all patients. For example, a 2016 Spanish study presented at the 2016 European League Against Rheumatism Annual Congress suggested antibody-positive patients being treated with Remicade should not be switched to treatment with the biosimilar infliximab because the antibodies will interact with the new drug and potentially lead to a loss of response. Lead author Daniel Nagore, MD, said, “While most studies show there are no significant differences in clinical response between a biosimilar and the original product, some physicians and patient advocacy groups have expressed concern about how interchangeable they really are, and whether it is safe to switch from the brand name version to the biosimilar.”
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.